Video
Journals
Specialty Area
Topics
Institute for Value-Based Medicine
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Advertisement
Contact Info
2 Commerce Drive
Cranbury, NJ 08512
© 2025 MJH Life Sciences
AJMC®
All rights reserved.
AJMC®
All rights reserved.
Social Determinants of Health
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Panelists discuss how social determinants such as access, income, and literacy drive disparities in LDL-C control.
EP: 1.Understanding the Current State of LDL-C Goal Attainment and Barriers to Adequate Control in Hyperlipidemia
EP: 2.Challenges with Undertreatment in Hyperlipidemia and Opportunities to Address this Gap
EP: 3.Pharmacy-Driven Challenges
EP: 4.Real-World Insights and PROMPT-LIPID
EP: 5.Social Determinants of Health
EP: 6.The 2013 Guideline Shift
EP: 7.Unintended Consequences of Metric Changes
EP: 8.Reinstating LDL-C Targets
EP: 9.International LDL Thresholds
EP: 10.Nonstatin Therapy Decisions
EP: 11.PCSK9 Inhibitor Underuse
EP: 12.Payer and Prior Authorization Barriers
EP: 13.Adherence and Persistence
EP: 14.Cumulative LDL-C Exposure
Panelists discuss how social determinants of health profoundly shape cholesterol control and patient engagement. Income, access to transportation, education, and health care coverage all influence adherence to low-density lipoprotein (LDL)–lowering therapy.
They emphasize that patients facing economic hardship are less likely to fill prescriptions, attend follow-up visits, or afford nonstatin agents. Cultural and language barriers further complicate communication around risk and treatment.
Panelists advocate for patient-centered strategies that integrate social support, care navigation, and community-based screening programs to reduce disparities in LDL cholesterol management.
FDA to Accept Deidentified Real-World Evidence for Select Medical Device Applications
December 15th 2025Today, the FDA issued new guidance allowing de-identified real-world evidence in certain medical device applications, removing a barrier to using large data sources.
Read More
Managed Care Cast Presents: New Evidence and Economic Considerations in IPF Care
November 25th 2025Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.
Listen
COVID-19 Vaccination in Pregnant Patients Reduces Hospitalization, Preterm Birth Across Variants
December 15th 2025COVID-19 vaccination during pregnancy lowers hospitalization and preterm birth risks, providing key guidance for maternal care strategies.
Read More
Inside the Discovery That Changed CML Treatment Forever: Jorge Cortes, MD
November 11th 2025Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival.
Listen
Orlowski Calls Linvoseltamab Results “the Best Single-Agent Data Ever in the History of Myeloma”
December 15th 2025Linvoseltamab shows promise as a first-line therapy for multiple myeloma, offering high response rates and a simplified treatment approach.
Read More
ICYMI: Highlights From AHA 2025 Scientific Sessions
December 15th 2025AHA 2025 highlights included new guidelines and targeted approaches advancing heart failure and cardiovascular care.
Read More
FDA to Accept Deidentified Real-World Evidence for Select Medical Device Applications
December 15th 2025Today, the FDA issued new guidance allowing de-identified real-world evidence in certain medical device applications, removing a barrier to using large data sources.
Read More
Managed Care Cast Presents: New Evidence and Economic Considerations in IPF Care
November 25th 2025Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.
Listen
COVID-19 Vaccination in Pregnant Patients Reduces Hospitalization, Preterm Birth Across Variants
December 15th 2025COVID-19 vaccination during pregnancy lowers hospitalization and preterm birth risks, providing key guidance for maternal care strategies.
Read More
Inside the Discovery That Changed CML Treatment Forever: Jorge Cortes, MD
November 11th 2025Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival.
Listen
Orlowski Calls Linvoseltamab Results “the Best Single-Agent Data Ever in the History of Myeloma”
December 15th 2025Linvoseltamab shows promise as a first-line therapy for multiple myeloma, offering high response rates and a simplified treatment approach.
Read More
ICYMI: Highlights From AHA 2025 Scientific Sessions
December 15th 2025AHA 2025 highlights included new guidelines and targeted approaches advancing heart failure and cardiovascular care.
Read More